Leveraging on 40+ years of biotechnological experience, Amgen has long been exploring impactful solutions for treating life-threatening illnesses, particularly in developing originator biologics and biosimilars to serve metastatic colorectal cancer (mCRC) patients.^1,2

Vectibix^®, the first fully human monoclonal antibody to epidermal growth factor receptor (EGFR), is an originator developed by Amgen for treating RAS-wide type mCRC.^3,4 As first-line treatment, Vectibix^® achieves early tumor shrinkage (ETS) and increases surgical resectability with FOLFOX4.^5,6 In the PRIME study, 59% of RAS-wide type patients on Vectibix® + FOLFOX4* achieved ETS ≥30% in 8 weeks vs. 38% in the FOLFOX4* only group (95% CI: 12.7-30.9; p<0.001).⁵

MVASI^TM, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody introduced by Amgen, is the first approved bevacizumab biosimilar in treating mCRC with proven efficacy, safety, immunogenicity and potency similar to originator in various studies.^7-10 In the MAPLE study, the efficacy of MVASI^TM was 39.0%, while the reference product was 41.7%, showing an equivalence in objective response rate (ORR).⁹ Also noteworthy is that MVASI^TM offers a potentially more affordable treatment to patients.⁹

With Vectibix^® and MVASI^TM, a total mCRC solution is made available to both RAS wildtype and mutant type metastatic colorectal cancer..^4,11

For more information about the medications, please refer to the full prescribing Information.

_{^*FOLFOX4: oxaliplatin 85mg/m² IV infusion on day 1 and leucovorin 200mg/m² (or equivalent) IV infusion followed by fluorouracil 400mg/m² IV bolus and 600mg/m² 22-hour continuous infusion on days 1 and 2.⁵ Repeat every 2 weeks.⁵}

_{HK-08528-MVA-2022-Jun}

_{Please scan the below QR codes for the prescribing information of MVASI^TM and Vectibix^®}

_MVASI^TM

_Vectibix^®